Abstract
Protein aggregation presents a significant challenge in the pharmaceutical drug development process, particularly for biologics and protein-based therapeutics. These aggregates can negatively impact drug efficacy, stability, and safety. This article explores the underlying mechanisms of protein aggregation, factors influencing it, and strategies to mitigate its effects during drug development. The study also discusses analytical methods for detecting aggregates and regulatory perspectives on aggregate control. Understanding and controlling protein aggregation is critical for enhancing drug formulation, storage, and delivery, ultimately leading to improved therapeutic outcomes.
References
Ahmad, N. R. (2025). Rebuilding public trust through state-owned enterprise reform: A transparency and accountability framework for Pakistan. Punjab Sahulat Bazaars Authority. https://doi.org/10.52152/6q2p9250
Ahmad, N. R. (2025). Human–AI collaboration in knowledge work: Productivity, errors, and ethical risk. https://doi.org/10.52152/6q2p9250

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Dr. Amina Rauf (Author)